Lee S. Schwartzberg

20.0k total citations · 3 hit papers
422 papers, 10.2k citations indexed

About

Lee S. Schwartzberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Lee S. Schwartzberg has authored 422 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Oncology, 144 papers in Pulmonary and Respiratory Medicine and 102 papers in Cancer Research. Recurrent topics in Lee S. Schwartzberg's work include Cancer Treatment and Pharmacology (94 papers), Nausea and vomiting management (77 papers) and Lung Cancer Treatments and Mutations (64 papers). Lee S. Schwartzberg is often cited by papers focused on Cancer Treatment and Pharmacology (94 papers), Nausea and vomiting management (77 papers) and Lung Cancer Treatments and Mutations (64 papers). Lee S. Schwartzberg collaborates with scholars based in United States, Germany and United Kingdom. Lee S. Schwartzberg's co-authors include Rudolph M. Navari, Arthur C. Houts, Robert Birch, B Hazelton, Mark S. Walker, Barry Fortner, Cathy Allen, W. H. West, Meinolf Karthaus and Peter Palmer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Lee S. Schwartzberg

402 papers receiving 9.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 478 citations Lee S. Schwartzberg, Fernando Rivera et al. Journal of Clinical Oncology profile →
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Tiffany A. Traina, Denise A. Yardley et al. Journal of Clinical Oncology profile →
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

2019 314 citations Sara M. Tolaney, Lee S. Schwartzberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lee S. Schwartzberg United States	49	6.0k	2.3k	1.7k	1.5k	1.5k	422	10.2k
Haralabos P. Kalofonos Greece	53	6.1k 1.0×	2.1k 0.9×	1.1k 0.6×	1.3k 0.9×	1.0k 0.7×	384	10.3k
Joanne Mortimer United States	47	4.4k 0.7×	3.0k 1.3×	2.0k 1.2×	1.8k 1.2×	371 0.3×	260	9.5k
J.W.R. Nortier Netherlands	44	3.5k 0.6×	1.2k 0.5×	681 0.4×	1.9k 1.3×	1.5k 1.1×	157	7.8k
Jeffrey Crawford United States	48	6.8k 1.1×	2.8k 1.2×	686 0.4×	731 0.5×	1.4k 0.9×	206	10.2k
Amanda L. Blackford United States	48	3.6k 0.6×	1.4k 0.6×	941 0.6×	1.3k 0.9×	639 0.4×	227	7.5k
Martee L. Hensley United States	55	4.2k 0.7×	4.7k 2.0×	1.6k 0.9×	1.1k 0.7×	1.5k 1.1×	223	13.3k
Patrick J. Flynn United States	51	6.9k 1.1×	2.6k 1.1×	1.4k 0.8×	1.6k 1.1×	471 0.3×	145	11.1k
James L. Wade United States	45	4.3k 0.7×	2.0k 0.8×	796 0.5×	1.3k 0.9×	1.2k 0.8×	153	7.6k
Shaker R. Dakhil United States	60	9.2k 1.5×	5.1k 2.2×	1.4k 0.8×	3.1k 2.1×	1.1k 0.8×	313	16.4k
Siqing Fu United States	51	4.1k 0.7×	2.4k 1.0×	837 0.5×	2.4k 1.7×	545 0.4×	412	9.6k

Countries citing papers authored by Lee S. Schwartzberg

Since Specialization

Citations

This map shows the geographic impact of Lee S. Schwartzberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee S. Schwartzberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee S. Schwartzberg more than expected).

Fields of papers citing papers by Lee S. Schwartzberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee S. Schwartzberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee S. Schwartzberg. The network helps show where Lee S. Schwartzberg may publish in the future.

Co-authorship network of co-authors of Lee S. Schwartzberg

This figure shows the co-authorship network connecting the top 25 collaborators of Lee S. Schwartzberg. A scholar is included among the top collaborators of Lee S. Schwartzberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee S. Schwartzberg. Lee S. Schwartzberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Graff, Stephanie L., Sara M. Tolaney, Lowell L. Hart, et al.. (2025). Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer. Cancer. 131(7). e35817–e35817.

O’Shaughnessy, Joyce, Sara M. Tolaney, Denise A. Yardley, et al.. (2025). Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer. The Breast. 81. 104437–104437. 1 indexed citations

Palmieri, Carlo, Hannah M. Linden, Stephen N. Birrell, et al.. (2024). Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. The Lancet Oncology. 25(3). 317–325. 20 indexed citations

Rinn, Kristine, Hannah M. Linden, Lee S. Schwartzberg, et al.. (2024). Abstract PO4-27-06: Design of Active Phase 3 ENABLAR-2 Study Evaluating Enobosarm +/- Abemaciclib in Patients with AR+ER+HER2- 2nd-Line Metastatic Breast Cancer Following Tumor Progression on an Estrogen Blocking Agent Plus Palbociclib or Ribociclib. Cancer Research. 84(9_Supplement). PO4–27. 1 indexed citations

Olver, Ian, Rebecca Clark-Snow, Christina H. Ruhlmann, et al.. (2023). 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Supportive Care in Cancer. 32(1). 37–37. 3 indexed citations

Hu, Xin, Cameron M. Kaplan, Michelle Y. Martin, et al.. (2022). Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 32(2). 167–174. 6 indexed citations

Wang, Jiajing, et al.. (2020). Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women. Breast Cancer Research and Treatment. 182(2). 247–258. 11 indexed citations

Schwartzberg, Lee S. & Gregory A. Vidal. (2020). Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. Clinical Breast Cancer. 20(4). e439–e449. 15 indexed citations

Abraham, Jame, Humberto Caldera, Robert E. Coleman, et al.. (2018). Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment. 169(1). 1–7. 9 indexed citations

10.

Schwartzberg, Lee S., Denise A. Yardley, Anthony Elias, et al.. (2017). A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical Cancer Research. 23(15). 4046–4054. 42 indexed citations

11.

Dillman, Robert O., Edward F. McClay, Neil M. Barth, et al.. (2015). Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer Biotherapy and Radiopharmaceuticals. 30(5). 187–194. 18 indexed citations

12.

Wilks, Sharon, Shannon Puhalla, Joyce O’Shaughnessy, et al.. (2014). Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer. Clinical Breast Cancer. 14(6). 405–412. 50 indexed citations

13.

McIntyre, Kristi, Joyce O’Shaughnessy, Lee S. Schwartzberg, et al.. (2014). Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Research and Treatment. 146(2). 321–328. 48 indexed citations

14.

Schwartzberg, Lee S., Fernando Rivera, Meinolf Karthaus, et al.. (2014). PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. Journal of Clinical Oncology. 32(21). 2240–2247. 478 indexed citations breakdown →

15.

Baselga, José, Frederico Costa, Henry Gómez, et al.. (2013). A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 14(1). 228–228. 31 indexed citations

16.

Schwartzberg, Lee S., Grace Wang, Bradley G. Somer, et al.. (2013). Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 14(1). 13–19. 42 indexed citations

17.

Tillmanns, Todd, M. Patrick Lowe, Mark S. Walker, Edward J. Stepanski, & Lee S. Schwartzberg. (2012). Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecologic Oncology. 128(2). 221–228. 40 indexed citations

18.

Robinson, Katherine, Michael E. Williams, Richard H. van der Jagt, et al.. (2008). Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 26(27). 4473–4479. 250 indexed citations

19.

Schwartzberg, Lee S., Lorrin Yee, B. Mirtsching, et al.. (2007). A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. 5. 22–23. 1 indexed citations

20.

Dillman, Robert O., Carol DePriest, Neil M. Barth, et al.. (2007). Patient-Specific Vaccines Derived from Autologous Tumor Cell Lines as Active Specific Immunotherapy: Results of Exploratory Phase I/II Trials in Patients with Metastatic Melanoma. Cancer Biotherapy and Radiopharmaceuticals. 22(3). 309–321. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact